Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 105
Filter
1.
Arq. bras. med. vet. zootec. (Online) ; 73(3): 560-570, May-June 2021. tab
Article in English | LILACS, VETINDEX | ID: biblio-1278353

ABSTRACT

The objective of this study was to compare the reproductive efficiency of dairy buffaloes undergoing fixed-time artificial insemination (FTAI) protocols based on progesterone/estrogen (P4/E2) and eCG during unfavorable breeding season using cooled (CS) and frozen semen (FS). A total of 446 buffaloes (> 40 days postpartum) were randomly distributed into four blocks (years): B1-2014 (n = 143), B2-2015 (n = 34), B3-2016 (n = 90), and B4-2017 (n = 179). Each block was subdivided into two (AI with CS and FS using the same ejaculate of each bull). Thus, the block subdivision was as follows: B1 (CS = 71 and FS = 72); B2 (CS = 18 and FS = 16); B3 (CS = 47 and FS = 43); and B4 (CS = 90 and FS = 89). The ejaculates of eight Murrah bulls collected using an artificial vagina were divided into two aliquots: one aliquot was diluted in Botu-Bov® commercial extender and cooled (BB-CS), and the other was diluted in the same extender and frozen (BB-FS). BB-CS aliquots were cooled at 5 °C/24 h using a refrigerator. BB-FS group aliquots were also cooled, and after equilibrating at 5 °C for 4 h, were placed in a 21-L Styrofoam box, 5 cm above the surface of liquid nitrogen. In the afternoon (A) on D0 (2:00 p.m.) the animals received EB 2.0 mg IM (Estrogin®) and an ear implant (CRESTAR® 3.0 mg P4). At D9 (A), the implant was removed, and the animals received eCG 400 IU IM (Folligon® 5000) + Cloprostenol PGF2α 0.530 mg IM (Sincrocio®). At D10 (A), the animals received EB 1.0 mg IM (Estrogin®), and at D12 (8:00 a.m.), AI was performed. At D42, pregnancy was diagnosed via ultrasonography. Total CRs were 48.2% CS and 34.6% FS for years 2014 to 2017, with a significant difference of 13.7% (P<0.05). In conclusion, cooled semen resulted in higher CR than frozen semen in dairy buffaloes under the P4/E2 and eCG FTAI during the unfavorable reproductive season.(AU)


O objetivo deste estudo foi comparar a eficiência reprodutiva de búfalas leiteiras submetidas a protocolos de inseminação artificial em tempo fixo (IATF) à base de progesterona/estrogênio (P4/E2) e eCG, durante a estação reprodutiva desfavorável, usando-se sêmen resfriado (SR) e congelado (SC) Um total de 446 búfalas (> 40 dias após o parto) foi distribuído aleatoriamente em quatro blocos (anos): B1-2014 (n = 143), B2-2015 (n = 34), B3-2016 (n = 90) e B4-2017 (n = 179). Cada bloco foi subdividido em dois (IA com SR e SC utilizando-se a mesma ejaculação de cada touro). Assim, a subdivisão do bloco foi a seguinte: B1 (SR = 71 e SC = 72); B2 (SR = 18 e SC = 16); B3 (SR = 47 e SC = 43); e B4 (SR = 90 e SC = 89). Os ejaculados de oito touros Murrah coletados com vagina artificial foram divididos em duas alíquotas: uma alíquota diluída em diluente comercial Botu-Bov® e resfriada (BB-SR), e a outra diluída no mesmo diluente e congelada (BB-SC). As alíquotas de BB-SR foram resfriados a 5°C/24h usando-se um refrigerador. As alíquotas do grupo BB-SC também foram resfriadas e, após equilíbrio a 5°C por 4h, foram colocadas em uma caixa de isopor de 21L, 5 cm acima da superfície do nitrogênio líquido. À tarde (A), no D0 (14h), os animais receberam BE 2,0 mg IM (Estrogin®) e um implante auricular (Crestar® 3,0 mg P4). No D9 (A), o implante foi retirado e os animais receberam eCG 400 UI IM (Folligon® 5000) + cloprostenol PGF2α 0,530 mg IM (Sincrocio®). No D10 (A), os animais receberam BE 1,0mg IM (Estrogin®), e, no D12 (8h da manhã), foram realizadas as IAs. No D42, a gestação foi diagnosticada por ultrassonografia. As taxas de concepção (TC) totais foram 48,2% SR e 34,6% SC para os anos de 2014 a 2017, com uma diferença significativa de 13,7% (P<0,05). Em conclusão, o sêmen resfriado resultou em maior TC do que o sêmen congelado em bubalinos leiteiros sob P4/E2 e eCG FTAI durante a estação reprodutiva desfavorável.(AU)


Subject(s)
Animals , Female , Semen Preservation/veterinary , Buffaloes/physiology , Estrus Synchronization , Progesterone/administration & dosage , Insemination, Artificial/veterinary , Estrogens/administration & dosage
2.
Braz. j. med. biol. res ; 53(1): e8659, Jan. 2020. graf
Article in English | LILACS | ID: biblio-1055485

ABSTRACT

Eosinophils are abundant in the reproductive tract, contributing to the remodeling and successful implantation of the embryo. However, the mechanisms by which eosinophils migrate into the uterus and their relationship to edema are still not entirely clear, since there are a variety of chemotactic factors that can cause migration of these cells. Therefore, to evaluate the role of CCR3 in eosinophil migration, ovariectomized C57BL/6 mice were treated with CCR3 antagonist SB 328437 and 17β-estradiol. The hypothesis that the CCR3 receptor plays an important role in eosinophil migration to the mouse uterus was confirmed, because we observed reduction in eosinophil peroxidase activity in these antagonist-treated uteruses. The antagonist also influenced uterine hypertrophy, inhibiting edema formation. Finally, histological analysis of the orcein-stained uteruses showed that the antagonist reduced eosinophil migration together with edema. These data showed that the CCR3 receptor is an important target for studies that seek to clarify the functions of these cells in uterine physiology.


Subject(s)
Animals , Female , Rabbits , Uterus/cytology , Cell Movement/drug effects , Eosinophils/drug effects , Estradiol/administration & dosage , Estrogens/administration & dosage , Receptors, CCR3/antagonists & inhibitors , Ovariectomy , Mice, Inbred C57BL
3.
Medwave ; 20(5): e7913, 2020.
Article in Spanish | LILACS | ID: biblio-1116984

ABSTRACT

INTRODUCCIÓN: La infección del tracto urinario es una patología frecuente, con un alto riesgo de recurrencia, por lo que representa un importan-te motivo de consulta. Dentro de la población más afectada se encuentran las mujeres postmenopáusicas debido a la caída de los niveles de estrógenos, tanto locales como sistémicos, perdiéndose la barrera protectora de la vía urinaria contra agentes patógenos. Entre las variadas medidas que potencialmente disminuirían el riesgo de infección urinaria se ha planteado el uso de estrógenos, sin embargo, no está claro si realmente son efectivos. MÉTODOS: Para responder esta pregunta utilizamos Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud a nivel mundial, la cual es mantenida mediante búsquedas en múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, reanalizamos los datos de los estudios primarios, realizamos un metanálisis, preparamos tablas de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos seis revisiones sistemáticas que en conjunto incluyen siete estudios primarios, de los cuales, cuatro son ensayos aleatorizados. Concluimos que no está claro si los estrógenos orales disminuyen el riesgo de desarrollar infección del tracto urinario sintomática, porque la certeza de la evidencia es muy baja.


Subject(s)
Humans , Female , Urinary Tract Infections/prevention & control , Postmenopause , Estrogens/administration & dosage , Randomized Controlled Trials as Topic , Administration, Oral , Databases, Factual
4.
Int. j. odontostomatol. (Print) ; 13(4): 418-427, dic. 2019. graf
Article in English | LILACS | ID: biblio-1056478

ABSTRACT

ABSTRACT: Tooth eruption requires resorption of the alveolar bone interposed between the tooth germ and the oral mucosa (coronal bone). The cells responsible for bone resorption are the osteoclasts and their activity can be reduced or inactivated by estrogen hormone. We aimed to investigate the effects of estrogen on the process of tooth eruption in rats. Thirty-three Wistar rats, aged two-to-17-days, were divided into control, sham and estrogen-treated groups. After daily injections with estrogen, the animals were euthanized and the jaws removed and processed for histological analysis. We performed clinical examination, morphological analysis, quantification of the number of osteoclasts on the surface of the coronal bone and immunohistochemical analysis of estrogen receptor type alpha (ERα). Estrogen therapy was effective, which could be confirmed by the higher estrogen plasma levels on treated animals. However, it had no effect on tooth development or tooth eruption. Progressive bone resorption was observed and the number of osteoclasts on coronal bone was not affected on hormoneinjected animals, allowing tooth to erupt at the same time observed in untreated animals. Immunohistochemistry for ERα confirmed the presence of this type of receptor in osteoclasts, osteoblasts and osteocytes. Taken together, our results showed that estrogen stimulation was not sufficient to decrease the number of osteoclasts on the coronal bone, supporting the idea that, although estrogen may have a protective activity on bone resorption, this may not apply to the alveolar bone that is meant to be resorbed during eruptive process.


RESUMEN: La erupción dental requiere la resorción del hueso alveolar interpuesto entre el germen dental y la mucosa oral (hueso coronal). Las células responsables de la resorción ósea son los osteoclastos y su actividad puede reducirse o inactivarse por la hormona del estrógeno. Objetivos: apuntamos a investigar los efectos del estrógeno en el proceso de la erupción dental en ratas. Treinta y tres ratas Wistar, de dos a 17 días de edad, se dividieron en grupos de control, Sham y se trataron con estrógenos. Los animales fueron eutanizados después del tratamento con estrógeno y se procesaron las mandíbulas para el análisis histológico. Se realizó el examen clínico, el análisis morfológico, la cuantificación del número de osteoclastos en la superficie del hueso coronal y el análisis inmunohistoquímico del tipo de receptor de estrógeno alfa (ERα). La terapia de estrógeno fue eficaz, lo que podría ser confirmado por los niveles plasmáticos más altos de estrógeno en los animales tratados. Sin embargo, no se observó ningún efecto sobre el desarrollo de los dientes o la erupción dental. Se observó una resorción ósea progresiva y el número de osteoclastos en el hueso coronal no se vio afectado en los animales inyectados con hormonas, permitiendo que el diente erupcionó durante el mismo período de tiempo observado en animales no tratados. La inmunohistoquímica para el ERα confirmó la presencia de este tipo de receptor en los osteoclastos, osteoblastos y osteocitos. Nuestros resultados mostraron que la estimulación del estrógeno no fue suficiente para reducir el número de osteoclastos en el hueso coronal confirmando que, si bien el estrógeno puede tener una actividad protectora en la resorción ósea, esto puede no se aplica al hueso alveolar que está destinado a ser rerecurrido durante el proceso eruptivo.


Subject(s)
Animals , Female , Rats , Tooth Eruption/physiology , Bone Resorption/physiopathology , Receptors, Estrogen , Bone Remodeling/physiology , Animal Experimentation , Osteoclasts , Immunohistochemistry/methods , Data Interpretation, Statistical , Ethics Committees , Rats, Wistar , Estradiol/pharmacology , Estrogens/administration & dosage , Estrogens/adverse effects , Estrogens/therapeutic use , Alveolar Process/physiology
5.
Rev. chil. obstet. ginecol. (En línea) ; 83(5): 527-550, nov. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-978127

ABSTRACT

ABSTRACT In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).


Subject(s)
Humans , Female , Societies, Medical/trends , Menopause , Estrogen Replacement Therapy , Estrogen Replacement Therapy/adverse effects , Risk Factors , Estrogens/administration & dosage
6.
Clinics ; 73: e86, 2018. tab
Article in English | LILACS | ID: biblio-890760

ABSTRACT

OBJECTIVE: The ideal dosage of cross-sex hormones remains unknown. The aim of this study was to evaluate the luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol and prolactin levels after low-dose estrogen therapy with or without cyproterone acetate in transgender women. METHODS: The serum hormone and biochemical profiles of 51 transgender women were evaluated before gonadectomy. Hormone therapy consisted of conjugated equine estrogen alone or combined with cyproterone acetate. The daily dose of conjugated equine estrogen was 0.625 mg in 41 subjects and 1.25 mg in 10 subjects, and the daily dose of cyproterone acetate was 50 mg in 42 subjects and 100 mg in one subject. RESULTS: Estrogen-only therapy reduced the testosterone, luteinizing hormone and follicle-stimulating hormone levels from 731.5 to 18 ng/dL, 6.3 to 1.1 U/L and 9.6 to 1.5 U/L, respectively. Estrogen plus cyproterone acetate reduced the testosterone, luteinizing hormone and follicle-stimulating hormone levels from 750 to 21 ng/dL, 6.8 to 0.6 U/L and 10 to 1.0 U/L, respectively. The serum levels of luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol and prolactin in the patients treated with estrogen alone and estrogen plus cyproterone acetate were not significantly different. The group receiving estrogen plus cyproterone acetate had significantly higher levels of gamma-glutamyltransferase than the group receiving estrogen alone. No significant differences in the other biochemical parameters were evident between the patients receiving estrogen alone and estrogen plus cyproterone acetate. CONCLUSION: In our sample of transgender women, lower estrogen doses than those usually prescribed for these subjects were able to adjust the testosterone and estradiol levels to the physiological female range, thus avoiding high estrogen doses and their multiple associated side effects.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Testosterone/blood , Cyproterone Acetate/administration & dosage , Estradiol/blood , Estrogens/administration & dosage , Transgender Persons , Androgen Antagonists/administration & dosage , Prolactin/blood , Luteinizing Hormone/blood , Retrospective Studies , Dose-Response Relationship, Drug , Drug Interactions , Estrogens/blood , Follicle Stimulating Hormone/blood
7.
Revista Digital de Postgrado ; 6(1): 11-27, jun. 2017. tab, graf
Article in Spanish | LILACS, LIVECS | ID: biblio-1096803

ABSTRACT

Comparar la calidad de vida (CV) en mujeres posmenopáusicas antes y después del tratamiento con Tibolona atendidas en la consulta ginecológica de la Maternidad "Dr. Armando Castillo Plaza", Maracaibo, Venezuela. Métodos: Investigación comparativa y aplicada, con diseño no experimental, y prospectivo, que incluyo una muestra de 100 pacientes posmenopáusicas, evaluadas antes y después de 6 y 12 meses de recibir la terapia de reemplazo hormonal con Tibolona oral (2,5mg/día) por medio del cuestionario Menopause Rating Scale (MRS).Resultados: 94 mujeres completaron el protocolo de estudio, determinándose que antes de comenzar el tratamiento la mayoría presentaba síntomas somáticos, psicológicos y genitourinarios severos, mientras que al cabo de 12 meses de tratamiento hubo una mejoría significativa en todos los síntomas estudiados (P= 0.000). Asimismo, se evidenció una mejora significativa en la CV luego del tratamiento con Tibolona, expresada por una regresión de las mediasen las puntuaciones alcanzadas con el MRS entre la medición inicial, a los 6 y a los 12 meses; con un porcentaje de cambio en la CV de las pacientes participantes de -38,33% y -82.20% después de 6 y 12 meses de la intervención farmacológica, los cuales resultaron de relevancia clínica y significancia estadística (P= 0.000). Conclusión: La terapia hormonal sustitutiva con Tibolona mejora la CV de las pacientes posmenopáusicas en todas sus dimensiones, sobre todo en cuanto a la disminución de los síntomas somáticos.Palabras clave: calidad de vida, menopausia, terapia de reemplazo hormonal, tibolona(AU)


To compare the quality of life (QOL) in postmenopausal women before and after treatment with Tibolone attending at the gynaecological consultation in the "Maternidad Dr. Armando Castillo Plaza", Maracaibo, Venezuela. Methods: Comparative and applied research with quasi experimental and prospective design, which included a sample of 100 postmenopausal women, evaluated before and after 6 and 12 months receiving hormone replacement therapy with oral Tibolone (2,5mg/day) through the questionnaire Menopause Rating Scale (MRS). Results: 94 women completed the study protocol, it was found that before treatment the majority had most somatic, psychological and severe genitourinary, while after 12 months of treatment there was a significant improvement in all symptoms studied (P = 0.000 .) We also demonstrated a significant improvement in QOL after treatment with Tibolone, expressed by a regression of the means of the scores obtained with the MRS between the initial measurement, at 6 and 12 months, with a percentage change in the CV of the patients participating -38.33% -82.20% and after 6 and 12 months of pharmacological intervention, which were of clinical relevance and statistical significance (P = 0.000). Conclusion: Hormone replacement therapy with Tibolone improves QOL of the postmenopausal patients in all its dimensions, especially in terms of reduction in somatic symptoms(AU)


Subject(s)
Humans , Female , Middle Aged , Postmenopause/drug effects , Hormone Replacement Therapy/adverse effects , Estrogens/administration & dosage , Quality of Life , Affect , Gynecology
8.
Reprod. clim ; 32(2): 127-131, 2017.
Article in Portuguese | LILACS | ID: biblio-883429

ABSTRACT

O câncer de mama (BCA) é uma das neoplasias mais frequentes em mulheres de vários países, a exposição excessiva aos estrogênios é um dos principais fatores de risco. Os ovários são as principais fontes de produção estrogênica endógena; porém, na menopausa essa produção cessa e a síntese extragonadal, sobretudo nas células mesenquimais do tecido adiposo, passa a ser a principal fonte de produção estrogênica, pois essas células apresentam aromatase, enzima que converte androgênios em estrogênios. Apoiada por fortes evidências clínicas, a reposição androgênica tem sido recomendada para o alívio de sintomas decorrentes da síndrome da insuficiência androgênica feminina, tais como fadiga, alterações do humor e quadros de depressão; além disso, estudos experimentais têm sugerido a possibilidade de uma plausível proteção da reposição androgênica contra o BCA. Nesses estudos, em que atuou por meio de seus receptores, a testosterona apresentou efeitos antiproliferativos, pró­apoptóticos e inibiu a atividade dos receptores estrogênicos e do crescimento de tumores mamários; evidências clínicas também apoiam o papel protetor dos androgênios na mama. Entretanto, outros estudos indicam que esse papel protetor depende do nível de atividade da aromatase; assim, a testosterona pode exercer um efeito inibidor direto no crescimento tumoral ao ligar­se ao seu receptor, porém ter um efeito estimulador indireto através de sua conversão para estrogênios pela aromatase. A obesidade e a insulina, além de múltiplos outros fatores, alguns dos quais são fatores de risco independentes para BCA, podem resultar na superexpressão da aromatase e ter como resultado aumento na produção localizada de estrogênios, os quais são fatores estimulantes do BCA. Estudos sobre a administração de testosterona em mulheres são escassos e controversos e não existem estudos que forneçam dados em termos de segurança desse uso em longo prazo. Assim, nesta revisão pretendemos mostrar como os androgênios atuam na mama. Frente às evidências atuais, o uso de androgênios em mulheres com fatores de risco para câncer de mama não é recomendado.(AU)


Breast cancer (BCAA) is one of the most frequent malignancies in women in several countries, which excessive exposure to oestrogens is one of the main risk factors. The ovaries are the main source of endogenous estrogen production; however, at menopause this production sessate and extra­gonadal synthesis, especially in ectomesenchymal cells from adipose tissue, turns the main source of estrogen production, since these cells express aromatase, an enzyme that converts androgens to estrogens. Supported by strong clinical evidence androgen replacement has been recommended for the relief of symptoms caused by female syndrome of androgen insufficiency, such as fatigue, mood swings and depression; Furthermore, experimental studies have suggested the possibility of protection of androgen replacement against BCA. In these studies, acting through their receptors, testosterone showed antiproliferative, proapoptotic and inhibited the activity of estrogen receptors and growth of mammary tumors; Clinical evidence also support the protective role of androgens in the breast. However, studies indicate that this protective role depends on the level of aromatase activity; for instance, testosterone can exert a direct inhibitory effect on tumor growth by binding to its receptor, but have an indirect effect by stimulating its conversion to oestrogens by aromatase. Obesity and insulin, as well as multiple other factors, some of which are independent risk factors for BCA, may result in overexpression of aromatase, resulting in increased localized production of estrogens, which are inducible factors of BCA. Studies on the administration of testosterone in women are scarce and controversial, and there are no studies that provide data in terms of long­term use of safety. Thus, in this review we intend to show how androgens act in the breast. Given the current evidence, the use of androgens in women with risk factors for breast cancer is not recommended.(AU)


Subject(s)
Humans , Female , Androgens/administration & dosage , Androgens/adverse effects , Aromatase , Breast Neoplasms , Estrogens/administration & dosage , Estrogens/adverse effects
9.
Motriz (Online) ; 23(4): e1017107, 2017. tab, graf, ilus
Article in English | LILACS | ID: biblio-895018

ABSTRACT

AIMS: The aim of the present study was to investigate the influence of resistance training (RT) and hormone replacement (HR) on MMP-2 activity, biomechanical and physical properties bone of ovariectomized (OVX) rats. METHODS: Sprague-Dawley female rats were grouped into six experimental groups (n = 11 per group): sham-operated sedentary (SHAM Sed), ovariectomized sedentary (OVX Sed), sham-operated resistance training (SHAM RT), ovariectomized resistance training (OVX RT), ovariectomized sedentary hormone replacement (OVX Sed-HR), and ovariectomized resistance training hormone replacement (OVX RT-HR). HR groups received implanted silastic capsules with a 5% solution of 17ß-estradiol (50 mg 17ß-estradiol/ml of sunflower oil). In a 12-week RT period (27 sessions; 4-9 climbs) the animals climbed a 1.1 m vertical ladder with weights attached to their tails. Biomechanical and physical bone analyses were performed using a universal testing machine, and MMP-2 activity analysis was done by zymography. RESULTS: Bone density and bone mineral content was higher in the RT and HR groups. The MMP-2 activity was higher in the RT and HR groups. The biomechanical analysis (stiffness, fracture load and maximum load) demonstrated better bone tissue quality in the RT associated with HR. CONCLUSION: The RT alone as well as when it is associated with HR was efficient in increasing MMP-2 activity, biomechanical and biophysical properties bone of ovariectomized rats.(AU)


Subject(s)
Animals , Female , Rats , Osteoporosis , Ovariectomy , Hormone Replacement Therapy , Metalloproteases/administration & dosage , Estradiol/administration & dosage , Estrogens/administration & dosage , Resistance Training
10.
Oman Medical Journal. 2017; 32 (1): 15-19
in English | IMEMR | ID: emr-185719

ABSTRACT

Objectives: To measure the effect of vaginal estrogen cream in the treatment of vaginal atrophy in menopausal Indian women


Methods: A total of 50 menopausal women aged between 40 and 80 years old with symptoms of vaginal atrophy were selected and treated with 0.5 g vaginal estrogen cream, twice weekly for 12 weeks. The women were followed up monthly where symptom score, Genital Health Clinical Evaluation [GHCE] score, vaginal pH, and vaginal maturation index [VMI] were assessed and compared to baseline data. Any adverse events were recorded


Results: There was a significant improvement [p < 0.010] in complaints such as vaginal dryness, itching, burning, and dyspareunia at the end of the study period. The clinical improvement of these patients was reflected in a decrease in GHCE score on every visit. Vaginal pH and VMI score also showed statistically significant improvements [p < 0.010]. No side effects with the drugs used were recorded during the study period


Conclusions: Vaginal estrogen cream causes symptomatic relief in women of menopausal age in India suffering from vaginal atrophy


Subject(s)
Adult , Aged , Aged, 80 and over , Middle Aged , Women , Vaginal Creams, Foams, and Jellies , Menopause , Estrogens/administration & dosage , Prospective Studies
11.
Acta cir. bras ; 31(10): 661-667, Oct. 2016. tab, graf
Article in English | LILACS | ID: biblio-827656

ABSTRACT

ABSTRACT PURPOSE: To develop a model for studying cerebrovascular disease prevention in elderly women. METHODS: Sixty 18-month-old Sprague Dawley (SD) rats were randomly divided into an estrogen administration group (EA, n=30) and a non-administration group (NA, n=30); thirty 4-month-old SD rats were allocated to a control group. The EA group received estradiol benzoate starting on the 5th day of a 34-day breeding period, and the serum levels of estradiol (E2), estrogen receptor (ER), and malondialdehyde (MDA) were measured. The MCA of each group was then sampled for viscoelastic experiments. RESULTS: The serum levels of E2 and MDA in the EA group showed significant differences compared to those in the control group (p<0.05), while the difference in ER between the EA and control groups was not significant (p>0.05). The decrease in MCA stress at 7,200 s and the increase in strain at 7,200 s in the EA group showed no significant differences compared to the control group (p>0.05). CONCLUSION: Estradiol administration inhibited the formation of lipid peroxidation products and restored middle cerebral arterial viscoelasticity in aged female rats.


Subject(s)
Animals , Female , Middle Cerebral Artery/drug effects , Estradiol/analogs & derivatives , Estrogens/pharmacology , Reference Values , Time Factors , Viscosity/drug effects , Lipid Peroxidation/drug effects , Random Allocation , Receptors, Estradiol/blood , Rats, Sprague-Dawley , Middle Cerebral Artery/physiology , Elasticity/drug effects , Estradiol/administration & dosage , Estradiol/blood , Estradiol/pharmacology , Estrogens/administration & dosage , Malondialdehyde/blood
12.
Braz. j. med. biol. res ; 49(1): 00601, 2016. tab, graf
Article in English | LILACS | ID: lil-765006

ABSTRACT

Drospirenone (DRSP) is a progestin with anti-aldosterone properties and it reduces blood pressure in hypertensive women. However, the effects of DRSP on endothelium-dependent coronary vasodilation have not been evaluated. This study investigated the effects of combined therapy with estrogen (E2) and DRSP on endothelium-dependent vasodilation of the coronary bed of ovariectomized (OVX) spontaneously hypertensive rats. Female spontaneously hypertensive rats (n=87) at 12 weeks of age were randomly divided into sham operated (Sham), OVX, OVX treated with E2 (E2), and OVX treated with E2 and DRSP (E2+DRSP) groups. Hemodynamic parameters were directly evaluated by catheter insertion into the femoral artery. Endothelium-dependent vasodilation in response to bradykinin in the coronary arterial bed was assessed using isolated hearts according to a modified Langendorff method. Coronary protein expression of endothelial nitric oxide synthase and estrogen receptor alpha (ER-α) was assessed by Western blotting. Histological slices of coronary arteries were stained with hematoxylin and eosin, and morphometric parameters were analyzed. Oxidative stress was assessed in situ by dihydroethidium fluorescence. Ovariectomy increased systolic blood pressure, which was only prevented by E2+DRSP treatment. Estrogen deficiency caused endothelial dysfunction, which was prevented by both treatments. However, the vasodilator response in the E2+DRSP group was significantly higher at the three highest concentrations compared with the OVX group. Reduced ER-α expression in OVX rats was restored by both treatments. Morphometric parameters and oxidative stress were augmented by OVX and reduced by E2 and E2+DRSP treatments. Hormonal therapy with E2 and DRSP may be an important therapeutic option in the prevention of coronary heart disease in hypertensive post-menopausal women.


Subject(s)
Animals , Female , Rats , Androstenes/administration & dosage , Coronary Vessels/drug effects , Endothelium, Vascular/drug effects , Estradiol/administration & dosage , Hormone Replacement Therapy/methods , Hypertension/drug therapy , Vasodilation/drug effects , Blotting, Western , Bradykinin/pharmacology , Combined Modality Therapy , Coronary Vessels/pathology , Estrogen Receptor alpha/drug effects , Estrogens/administration & dosage , Ethidium/analogs & derivatives , Femoral Artery , Hemodynamics , Mineralocorticoid Receptor Antagonists/administration & dosage , Nitric Oxide Synthase Type III/drug effects , Ovariectomy , Oxidative Stress/drug effects , Random Allocation , Rats, Inbred SHR , Vasodilator Agents/pharmacology
13.
Acta cir. bras ; 30(1): 6-12, 01/2015. tab, graf
Article in English | LILACS | ID: lil-735705

ABSTRACT

PURPOSE: To present a rat model of subcutaneous endometriosis for the study of pathophysiology and the effects of drugs. METHODS: Fifty three-month-old female Wistar rats (Rattus norvergicus) were distributed into one control group and four treatment groups: estradiol (2.5; 5; 10mg/kg sc), medroxyprogesterone acetate (0.5; 2; 5mg/kg sc), triptorelin pamoate (0.18; 0.56mg/kg sc) and acetylsalicylic acid (3mg/kg per os). The animals were autoimplanted subcutaneously with 4x4-mm uterine fragments to induce endometriosis. The endometriomas were measured on days 1, 7, 14 and 21. The relative dry and wet weights of the endometrioma were used to evaluate response to the drug. Endometrial -like tissue was confirmed by histology. The greatest weight gain was observed on day 14 (relative wet weight: 29.1 ± 6.7mg%, relative dry weight: 5.3 ± 0.9mg %). Treatments were administered between day 5 and day 14. RESULTS: The relative wet weight of the hemiuterus in the 10mg/kg estradiol group differed significantly from control and the other two estradiol groups (p=0.0001). In the medroxyprogesterone acetate group the weight decreased significantly but this decrease was not dose-dependent. Weight reduction was also significant in the triptorelin pamoate and the acetylsalicylic acid groups. CONCLUSION: The model of subcutaneous endometriosis is reproducible, low-cost and easy to perform, and suitable for the study of pathophysiology and the effects of drugs. .


Subject(s)
Animals , Female , Connective Tissue Diseases/drug therapy , Connective Tissue Diseases/physiopathology , Disease Models, Animal , Endometriosis/drug therapy , Endometriosis/physiopathology , Subcutaneous Tissue , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Antineoplastic Agents, Hormonal/administration & dosage , Aspirin/administration & dosage , Connective Tissue Diseases/pathology , Dose-Response Relationship, Drug , Endometriosis/pathology , Estradiol/administration & dosage , Estrogens/administration & dosage , Medroxyprogesterone Acetate/administration & dosage , Rats, Wistar , Reproducibility of Results , Time Factors , Triptorelin Pamoate/administration & dosage
14.
Rev. bras. ginecol. obstet ; 36(6): 251-258, 06/2014. tab, graf
Article in English | LILACS | ID: lil-716360

ABSTRACT

PURPOSE: To assess the effects of a soy dietary supplement on the main biomarkers of cardiovascular health in postmenopausal women compared with the effects of low-dose hormone therapy (HT) and placebo. METHODS: Double-blind, randomized and controlled intention-to-treat trial. Sixty healthy postmenopausal women, aged 40-60 years, 4.1 years mean time since menopause were recruited and randomly assigned to 3 groups: a soy dietary supplement group (isoflavone 90mg), a low-dose HT group (estradiol 1 mg plus noretisterone 0.5 mg) and a placebo group. Lipid profile, glucose level, body mass index, blood pressure and abdominal/hip ratio were evaluated in all the participants at baseline and after 16 weeks. Statistical analyses were performed using the χ2 test, Fisher's exact test, Kruskal-Wallis non-parametric test, analysis of variance (ANOVA), paired Student's t-test and Wilcoxon test. RESULTS: After a 16-week intervention period, total cholesterol decreased 11.3% and LDL-cholesterol decreased 18.6% in the HT group, but both did not change in the soy dietary supplement and placebo groups. Values for triglycerides, HDL-cholesterol, glucose level, body mass index, blood pressure and abdominal/hip ratio did not change over time in any of the three groups. CONCLUSION: The use of dietary soy supplement did not show any significant favorable effect on cardiovascular health biomarkers compared with HT. Clinical Trial Registry: The trial is registered at the Brazilian Clinical Trials Registry (Registro Brasileiro de Ensaios Clínicos - ReBEC), number RBR-76mm75. .


OBJETIVO: Avaliar os efeitos do uso de um suplemento alimentar à base de soja sobre os principais marcadores de risco cardiovascular e compará-los com o uso da terapia hormonal (TH) de baixa dose e grupo placebo em mulheres na pós-menopausa. MÉTODOS: Foram selecionadas 60 participantes do ambulatório de menopausa com idade entre 40 e 60 anos, com idade média de 4,1 anos na menopausa para participar de um ensaio clínico randomizado, duplo-cego e controlado com duração de 16 semanas. As pacientes foram randomizadas em 3 grupos: um grupo que recebeu suplemento dietético à base de soja (isoflavona 90 mg), um grupo que recebeu TH em baixa dose (estradiol 1 mg e noretisterona 0,5 mg) e um grupo placebo. Os seguintes parâmetros foram avaliados no início e ao término das 16 semanas de intervenção: perfil lipídico, glicemia de jejum, índice de massa corpórea, pressão sanguínea arterial e circunferência abdominal. A análise estatística foi realizada usando-se o teste do χ2, teste exato de Fisher, teste não paramétrico de Kruskal-Wallis, análise de variância (ANOVA), teste t de Student pareado e teste de Wilcoxon. RESULTADOS: Ao final do período de intervenção de 16 semanas, houve uma diminuição do colesterol total em 11,3% e do LDL-colesterol em 18,6% no grupo da TH, porém ambos não tiveram mudanças tanto no grupo do suplemento alimentar à base de soja quanto no grupo placebo. Os valores de triglicérides, HDL-colesterol, glicemia de jejum, índice de massa corpórea, pressão sanguínea arterial e circunferência abdominal não mudaram ao longo da intervenção em nenhum dos grupos estudados. CONCLUSÃO: Do ponto de vista cardiovascular, o suplemento alimentar à base de soja não mostrou efeito ...


Subject(s)
Adult , Female , Humans , Middle Aged , Dietary Supplements , Estrogen Replacement Therapy , Isoflavones/administration & dosage , Soy Foods , Biomarkers/blood , Cardiovascular Physiological Phenomena , Double-Blind Method , Estrogens/administration & dosage
15.
Arq. neuropsiquiatr ; 71(5): 313-319, maio 2013. graf
Article in English | LILACS | ID: lil-674229

ABSTRACT

In addition to antioxidative effects, estrogens also exert pro-oxidative actions. The effect of chronic administration of a high dose of estradiol valerate on Morris water maze tasks and brain tissues oxidative damage was investigated. The Sham-Est and OVX-Est groups were treated with estradiol valerate (4 mg/kg) for 12 weeks. Escape latency and traveled path in the Sham-Est and OVX-Est groups were significantly higher than in the Sham and OVX groups (p≪0.01 and p≪0.001). In the probe trial, the animals of the Sham-Est and OVX-Est groups spent lower time in Q1 compared to Sham and OVX groups (p≪0.05 and p≪0.001). In Sham-Est and OVX-Est groups, the brain tissue total thiol concentration was significantly lower, and malondialdehyde (MDA) concentrations were higher than in the Sham and OVX groups (p≪0.05 and p≪0.001). It is concluded that administration of high exogenous levels of estradiol impairs performance and enhances oxidative stress.


Além dos efeitos antioxidantes, os estrógenos também têm ação pró-oxidativa. Foi investigado o efeito da administração crônica de alta dose de valereato de estradiol no desempenho do labirinto aquático de Morris e o dano oxidativo ao tecido cerebral. Os grupos Sham-Est e OVX-Est foram tratados com valereato de estradiol (4 mg/kg) por 12 semanas. O tempo de latência para escapada e o caminho percorrido foram significativamente maiores nos grupos Sham-Est e OVX-Est em relação aos grupos Sham e OVX (p≪0,01 e p≪0,001). No estudo probe, os animais dos grupos Sham-Est e OVX-Est levaram menos tempo no Q1 em comparação aos grupos Sham e OVX (p≪0,05 e p≪0,001). Nos grupos Sham-Est e OVX-Est, a concentração total de tiol foi significativamente menor, enquanto a concentração de malondialdehydo (MDA) for maior do que aquela dos grupos Sham e OVX (p≪0,05 e p≪0,001). Concluiu-se que a administração de altas doses de estradiol exógeno compromete o desempenho e aumenta o estresse oxidativo naqueles animais.


Subject(s)
Animals , Female , Rats , Brain/drug effects , Estradiol/analogs & derivatives , Maze Learning/drug effects , Memory/drug effects , Ovariectomy , Oxidative Stress/drug effects , Dose-Response Relationship, Drug , Estradiol/administration & dosage , Estradiol/adverse effects , Estrogens/administration & dosage , Estrogens/adverse effects , Malondialdehyde/analysis , Rats, Wistar , Time Factors , Treatment Outcome
16.
IJRM-Iranian Journal of Reproductive Medicine. 2012; 10 (3): 219-222
in English | IMEMR | ID: emr-144281

ABSTRACT

About 75% of the symptomatic patients who involved with endometriosis have pelvic pain and dysmenorrhea. Pentoxifyllin is one of the drugs that according to its mechanism could be effective for pain relief of endometriosis which has been used for endometriosis treatment recently. We conducted a comparative study for detecting the effect of pentoxifylin [as an immonomodelator] in preventing recurrence endometriotic pain with pentoxifylin plus a combined contraceptive pill with low dose estrogen [LD] and also the LD pill alone. This was a comparative clinical trial on 83 patients with the chief complaint [CC] of pain [dysmenorrheal /or pelvic pain] and with the end diagnosis of endometriosis, in an operative laparoscopy. Patients, dividing to 3 groups, were treated with pentoxifylin, pentoxifylin+LD and LD alone for 10 months. The severity of pain [dismenorhea and/or pelvic pain] was detected by visual analogue scale [VAS] before and after the treatment. The severity of endometriosis in the patients was: I in class I and II in class II and III in class III. The groups were matched for the pain. The number of the patients in group 1, 2 and 3 were 28, 28 and 27 respectively. The pain was reduced in the groups of pentoxifylin+LD [p<0.001] and LD alone [p=0.00]. The pain relief was not significant in the group of pentoxifylin alone [p=0.136]. After treatment, the severity of pain was not significantly different between the LD group and the LD+penthoxyfillin group, but there was difference between these two groups and the group of penthoxyfillin alone. This study showed that penthoxyfillin actually could not have any effect on the pain relief of endometriosis. It also made it clear that penthoxyfillin could not increase the efficacy of LD when used with this medication


Subject(s)
Humans , Female , Adult , Pentoxifylline , Estrogens , Estrogens/administration & dosage , Treatment Outcome
17.
Rev. chil. pediatr ; 82(5): 432-438, oct. 2011. tab
Article in Spanish | LILACS | ID: lil-612173

ABSTRACT

Turner's Syndrome is the most frequent cause of female hypogonadism. Puberty must be pharmacologically induced in over 80 percent of these girls. Induction must be completed in a manner closest to physiology as possible. It is recommended that this induction be initiated at age 12 y.o. with natural estrogens (17 beta estradiol) in low dosage, equivalent to 1/10 a 1/8 of substitution dose, increasing stepwise and adding, after two years, a progestin to generate a menstruation. This revision shows various proposed schemes, as well as therapeutic alternatives available in Chile.


El síndrome de Turner es la causa más frecuente de hipogonadismo femenino. La pubertad tiene que ser inducida farmacológicamente en más del 80 por ciento de estas niñas. Esta inducción debe hacerse de la forma más fisiológica posible. Se recomienda iniciar esta inducción a los 12 años de edad cronológica, con estrógenos naturales (17 beta estradiol) en dosis bajas, equivalentes a 1/10 a 1/8 de la dosis de sustitución, aumentando la dosis por peldaños y agregando luego de dos años una progestina cíclica para generar una menstruación. En esta revisión se muestran los diversos esquemas propuestos en la literatura así como las alternativas terapéuticas existentes en Chile.


Subject(s)
Humans , Female , Child , Estrogens/therapeutic use , Hypogonadism/drug therapy , Puberty , Turner Syndrome/drug therapy , Growth , Drug Administration Schedule , Estrogens/administration & dosage
18.
Rev. chil. neuropsicol. (En línea) ; 6(1): 34-41, jul. 2011. tab
Article in Spanish | LILACS | ID: lil-609935

ABSTRACT

Las funciones cognitivas, como el aprendizaje, la memoria y las funciones ejecutivas, son afectadas por las hormonas esteroides sexuales. El objetivo fue evaluar el perfil cognoscitivo en personas transexuales hombre a mujer (TH-M) en presencia y ausencia de tratamiento hormonal con estrógenos. Participaron un total de 54 sujetos. El grupo experimental fue de 22 pacientes TH-M, dividido en dos grupos: con tratamiento hormonal (n=9) y sin tratamiento hormonal (n=13). El grupo control fue conformado por hombres (n=16) y mujeres (n=16), pareados en edad y escolaridad. Evaluados con la batería NEUROPSI: Atención y Memoria (Ostrosky-Solís, Gómez, Matute, Roselli, Ardila & Pineda, 2003). Los grupos transexuales tuvieron mejores puntajes que los controles en atención inmediata y en formación de categorías, pero mostraron menores puntajes que los controles en codificación de material visoespacial y de caras, en memoria verbal inmediata y evocada. Se encontraron correlaciones negativas entre meses de tratamiento y la codificación visoespacial, memoria para caras y memoria verbal. Los resultados sugieren que las hormonas sexuales tienen efectos organizadores y activadores sobre la cognición.


Mental functions, including learning, executive functions and memory, are susceptible to be affected by sexual steroids hormones. The objective was to evaluate the cognitive profile of transsexual’s male to female (TM-F) in presence and absence of hormonal treatment with estrogens. A total of 54 subjects participated. The experimental group was conformed by 22 patients in condition transsexual male to female, divided in two groups: with hormonal treatment (n=9) and without hormonal treatment (n=13). The control group was conformed by heterosexual men (n=16) and women (n=16) paired in age and schooling to the experimental group. Subjects were evaluated by a comprehensive neuropsychological battery, NEUROPSI: Attention and Memory (Ostrosky-Solís, Gómez, Matute, Roselli, Ardila & Pineda, 2003). Transsexual’s groups performed better than controls in immediate attention, category formation, but worse than controls in visuospatial codification, faces, recall and immediate verbal memory. Negative correlations were founded between treatment months in visuospatial codification, faces, and verbal memory.


Subject(s)
Humans , Male , Cognition , Executive Function , Estrogens/administration & dosage , Transsexualism/psychology , Transsexualism/drug therapy , Learning , Case-Control Studies , Estrogens/adverse effects , Feminization , Memory , Neuropsychological Tests , Sex Reassignment Procedures
19.
Femina ; 39(7): 373-378, jul. 2011.
Article in Portuguese | LILACS | ID: lil-613325

ABSTRACT

Devido aos efeitos adversos dos contraceptivos hormonais, algumas mulheres são privadas de seus benefícios, que se estendem além da contracepção. Especialmente em adolescentes, é preocupante o impacto dos hormônios sobre o osso. Buscando reunir evidências nesse sentido, três revisores independentes fizeram buscas nas bases de dados Medline, Lilacs, Ibecs, Scielo e Cochrane, utilizando descritores relacionados à contracepção e densidade óssea. Foram critérios de inclusão: revisões sistemáticas e estudos com nível de evidência A e B. Foram excluídos estudos com contraceptivos utilizados para fins terapêuticos e não contraceptivos. Das 66 publicações encontradas, foram selecionados 15 estudos, e evidenciou-se que compostos com progesterona isolada de depósito e possivelmente os de baixa dose estrogênica têm impacto negativo na fase do pico de massa óssea. Contudo, o efeito esteve restrito à idade de iniciação e ao tempo de uso, havendo recuperação após interrupção da contracepção. Não há evidências de relação entre uso de contraceptivos e fraturas. O aconselhamento contraceptivo deve considerar o efeito negativo que a progesterona isolada de depósito e a baixa dose estrogênica podem ter sobre a massa óssea na adolescência, considerando que tal efeito é reversível e limitado ao tempo de uso


Due to the adverse effects of hormonal contraceptives, some women are deprived of the benefits they provide that extend beyond contraception. In adolescents, the main concern is the impact hormones can have on their bone structure. Three independent reviewers researched the databases Medline, Lilacs, Ibecs, Scielo and Cochrane, by using descriptions related to contraception and bone density. The inclusion criteria were: systematic reviews and studies with levels of evidence A and B. Contraceptives used for therapeutic purposes, other than contraception itself, were excluded from the study. Of the 66 publications found, 15 studies were selected. Compounds isolated from progesterone deposit, and possibly the low-dose estrogen, have a negative impact on the stage the bone mass peaks, but the effect was restricted to the age of initiation and the time of use, with recovery after discontinuation of contraception. There is no evidence of a relationship between the use of contraceptives and bone fractures. The negative effects that the deposit of progesterone and low-dose estrogen may have on bone mass should be taken into account when adolescents engage in the use of contraceptives ? bearing in mind that said effects are reversible and limited to the time of use


Subject(s)
Humans , Female , Adolescent , Adolescent , Medroxyprogesterone Acetate/administration & dosage , Medroxyprogesterone Acetate/adverse effects , Contraceptive Agents, Female/adverse effects , Bone Density , Medroxyprogesterone Acetate/pharmacology , Contraceptives, Oral, Combined/administration & dosage , Delayed-Action Preparations , Estrogens/administration & dosage , Bone and Bones , Bone and Bones/metabolism
20.
Rev. panam. salud pública ; 29(6): 404-408, June 2011. tab
Article in English | LILACS | ID: lil-608270

ABSTRACT

OBJECTIVE: To compare the proportion of patients choosing surgical versus medical castration to treat prostate cancer, before and after the National Health Fund (NHF) of Jamaica began to subsidize hormone therapy. METHODS: A retrospective review was performed at the University Hospital of the West Indies (UHWI), Jamaica. The pathology database at UHWI was searched to identify patients who had prostate biopsies between January 2000 and December 2007. These were combined with records of biopsies at external institutions. Medical records of all patients with positive prostate biopsies were reviewed to determine if they had received androgen deprivation therapy (ADT). Patients were classified as having had surgical castration (bilateral orchiectomy) or medical castration. Chi-square statistics were used to determine the difference in proportions between those choosing medical versus surgical castration before and after March 2005, when the NHF began offering subsidies for ADT drugs. RESULTS: Of the 1 529 prostate biopsies performed during the study period, 680 (44.0 percent) cases of prostate cancer were diagnosed. Of these, 458 patients underwent ADT and had complete records available for analysis. The mean patient age was 72 years. During the entire study period, surgical castration was performed in 265 patients (58.0 percent) and medical castration in 193 (42.0 percent). A greater proportion of orchiectomies were performed before March 2005, rather than after (P < 0.001). Estrogens were the most common method of medical castration used before the NHF subsidy became available (62.0 percent); while luteinizing hormone-releasing hormone analogues (38.0 percent) and antiandrogens (36.5 percent) were most often chosen afterwards. CONCLUSIONS: Surgical castration was more common than medical castration before March 2005. After the NHF began to subsidize the cost of drugs for hormone therapy, medical castration was chosen more often. Increased access to drugs for hormone therapy has changed treatment patterns in Jamaica.


OBJETIVO: Comparar la proporción de pacientes que eligen la castración quirúrgica frente a la castración farmacológica para tratar el cáncer de próstata, antes y después de la creación de un subsidio del Fondo Nacional de Salud (NHF, por sus siglas en inglés) de Jamaica destinado a cubrir los costos de la hormonoterapia. MÉTODOS: Se llevó a cabo un examen retrospectivo en el Hospital Universitario de las Indias Occidentales, Jamaica. Se efectuó una búsqueda en la base de datos de enfermedades de dicho hospital para identificar a los pacientes a quienes se les había practicado una biopsia de próstata entre enero del 2000 y diciembre del 2007. Los datos se combinaron con los registros de biopsias llevadas a cabo en instituciones externas. Se estudiaron las historias clínicas de todos los pacientes con resultados positivos en la biopsia de próstata para determinar si habían recibido tratamiento de supresión androgénica. Los pacientes se clasificaron en dos grupos, según se hubieran tratado mediante castración quirúrgica (orquiectomía bilateral) o farmacológica. Se usó la prueba de la ji al cuadrado para determinar la diferencia en las proporciones entre los pacientes que escogieron la castración quirúrgica y los que escogieron la opción farmacológica antes y después de marzo del 2005, la fecha en la que el NHF empezó a subsidiar los medicamentos de supresión androgénica. RESULTADOS: Entre las 1 529 biopsias de próstata realizadas durante el período de estudio, hubo 680 (44,0 por ciento) casos con diagnóstico de cáncer de próstata. De estos, 458 pacientes habían recibido tratamiento de supresión androgénica y se disponía de sus registros completos para el análisis. La edad media de los pacientes fue de 72 años. Durante el período de estudio, se les practicó castración quirúrgica a 265 pacientes (58,0 por ciento) y castración farmacológica a 193 (42,0 por ciento). La proporción de orquiectomías fue mayor antes de marzo del 2005 que después de esa fecha (P < 0,001). Los estrógenos fueron el método de castración farmacológica más común antes de la creación del subsidio del NHF (62,0 por ciento); a partir de ese momento se eligieron con mayor frecuencia los análogos de la hormona liberadora de la hormona luteinizante (38,0 por ciento) y los antiandrógenos (36,5 por ciento). CONCLUSIONES: La castración quirúrgica era más común que la castración farmacológica antes de marzo del 2005. Después de que el NHF empezó a subsidiar el costo de los medicamentos para el tratamiento hormonal, la opción escogida con más frecuencia fue la castración farmacológica. El mayor acceso a los medicamentos usados en la hormonoterapia ha cambiado los patrones de tratamiento del cáncer de próstata en Jamaica.


Subject(s)
Aged , Humans , Male , Adenocarcinoma/drug therapy , Antineoplastic Agents, Hormonal/economics , Financing, Government , Health Policy/economics , Insurance, Pharmaceutical Services/economics , National Health Programs , Prescription Fees , Prostatic Neoplasms/drug therapy , Adenocarcinoma/diagnosis , Adenocarcinoma/epidemiology , Adenocarcinoma/surgery , Androgen Antagonists/administration & dosage , Androgen Antagonists/economics , Androgen Antagonists/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Biopsy , Estrogens/administration & dosage , Estrogens/economics , Estrogens/therapeutic use , Gonadotropin-Releasing Hormone/agonists , Health Services Accessibility , Jamaica/epidemiology , Orchiectomy/economics , Orchiectomy/psychology , Orchiectomy , Patient Preference , Prostate/pathology , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/epidemiology , Prostatic Neoplasms/surgery , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL